Another phase I clinical trial evaluating guadecitabine with anti-CTLA-4 showed promising tumor immunomodulatory and anti-cancer activities in CM metastatic patients; briefly, the use of DNMTi led to the induction of HLA class I molecules and IFNƔ signaling pathways and increased tumor infiltration by CD8+ T cells, rendering those tumors more sensitive to immunotherapy [214]. Here, CTLA4 is linked to neoplasm.